Business
Abivax Announces Closing of $920 Million Public Offering
Abivax Announces Closing of $920 Million Public
About this update from Abivax Sa
EQS-News: ABIVAX / Key word(s): Capital Increase Abivax Announces Closing of $920 Million Public Offering 06.07.2026 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement.Abivax Announces Closing of $920 Million Public OfferingPARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 7,360,000 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “Offering”), which includes the full exercise of the underwriters’ option to purchase additional ADSs (the “Underwriters’ Option”). The aggregate gross proceeds, after exercise of the Underwriters’ Option, amounted to approximately $920.0 million, equivalent to approximately €807.4 million[1], before deduction of underwriting commissions and estimated expenses payable by the Company, and the estimated net proceeds, after deducting underwriting commissions and estimated offering expenses payable by the Company, will be approximately $874.1 million, equivalent to approximately €767.1 million¹. All of the ADSs in the Offering were offered by Abivax. The Company believes that the net proceeds from the Offering, together with its current cash and cash equivalents, will allow it to finance its operations into the fourth quarter of 2029. Abivax’s Ordinary Shares are listed on the regulated market of Euronext Paris under the symbol “ABVX” and its ADSs are listed on the Nasdaq Global Market under the symbol “ABVX”. Leerink Partners, Morgan Stanley, Piper Sandler and Guggenheim Securities acted as joint bookrunning managers for the Offering. LifeSci Capital acted as a passive bookrunning manager for the Offering. Van Lanschot Kempen acted as lead manager for the Offering. In accordance with Article 6 of Delegated Regulation (EU) 2016/1052 of March 8, 2016, Leerink Partners, acting as the stabilizing agent on its own behalf and on behalf of the other underwriters, reported that no stabilization activit...